Literature DB >> 30054321

Successful management of persistent distressing neuropsychiatric symptoms by clozapine in a patient suffering from dementia with Lewy bodies.

Manraj Bhamra1,2, Anto P Rajkumar1,2, Dominic H Ffytche1,2, Chris Kalafatis1,2.   

Abstract

Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia associated with poor prognosis and high carers' burden. Neuropsychiatric symptoms worsen this prognosis and are a high source of distress for service users and their carers. However, there is currently insufficient evidence to support the pharmacological and non-pharmacological management of these symptoms. Acetylcholinesterase inhibitors are the first-line pharmacological option, but challenging risky behaviours may persist despite their use. Antipsychotic medications are indicated in such clinical scenarios, but there is very limited evidence to support the efficacy and safety of these medications for managing neuropsychiatric symptoms in DLB. Hence, we report an individual with DLB with severe distressing persistent visual hallucinations and agitation. After multiple treatment options had failed, clozapine was successfully initiated with substantial improvement in both clinical and functional outcomes. Further studies are warranted for evaluating the efficacy of clozapine in managing neuropsychiatric symptoms in DLB. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  drugs: psychiatry; memory disorders; memory disorders (psychiatry); psychiatry (drugs and medicines); psychiatry of old age

Mesh:

Substances:

Year:  2018        PMID: 30054321     DOI: 10.1136/bcr-2018-224710

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  1 in total

1.  Exploring pathways to Hospital Care for Patients with Alzheimer's disease and related dementias in rural South Western Uganda.

Authors:  Nathan Kakongi; Godfrey Zari Rukundo; Bizu Gelaye; Edith K Wakida; Celestino Obua; Elialilia S Okello
Journal:  BMC Health Serv Res       Date:  2020-06-03       Impact factor: 2.908

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.